These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9621405)

  • 1. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects.
    Clément O; Siauve N; Cuénod CA; Frija G
    Top Magn Reson Imaging; 1998 Jun; 9(3):167-82. PubMed ID: 9621405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
    Petersein J; Saini S; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real enhancement or merely increased contrast?
    Chen JH
    AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
    [No Abstract]   [Full Text] [Related]  

  • 4. [Overview of MRI contrast media. The case of endorem].
    Duroux M
    Radiologe; 1995 Nov; 35(11 Suppl 2):S247-8. PubMed ID: 8588029
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
    Saini S; Edelman RR; Li W; Petersein J; Hahn PF
    Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
    [No Abstract]   [Full Text] [Related]  

  • 6. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
    Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
    AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The characterization value of feridex-enhanced MR imaging for focal hepatic lesions in reference to their histological pathology].
    Yang HF; Zhou XP; Yu JQ; Song B; Guang YS; Zhang HY; Chen X
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):548-50. PubMed ID: 16042902
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions.
    Ros PR; Freeny PC; Harms SE; Seltzer SE; Davis PL; Chan TW; Stillman AE; Muroff LR; Runge VM; Nissenbaum MA
    Radiology; 1995 Aug; 196(2):481-8. PubMed ID: 7617864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MR contrast agent: resovist (SH U 555A)].
    Nakajima H; Ichikawa T
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():328-32. PubMed ID: 11761967
    [No Abstract]   [Full Text] [Related]  

  • 10. Will ferumoxides-enhanced MR imaging replace CT during arterial portography in the detection of hepatic metastases? Prologue to a promising future.
    Soyer P
    Radiology; 1996 Sep; 200(3):610-1. PubMed ID: 8756902
    [No Abstract]   [Full Text] [Related]  

  • 11. [The MR tomography of focal liver lesions with the superparamagnetic contrast agent AMI-25 at 1.5 tesla].
    Duda SH; Laniado M; Kopp AF; Grönewäller E; Aicher KP; Pavone P; Jehle E; Claussen CD
    Rofo; 1994 Jan; 160(1):46-51. PubMed ID: 8305692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Superparamagnetic iron particles. The clinical results in the MR diagnosis of liver metastases].
    Ham B; Reichel M; Vogl T; Taupitz M; Wolf KJ
    Rofo; 1994 Jan; 160(1):52-8. PubMed ID: 8305693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles.
    Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Takahashi M
    J Comput Assist Tomogr; 1995; 19(4):665-7. PubMed ID: 7622710
    [No Abstract]   [Full Text] [Related]  

  • 15. [Focal intrahepatic siderosis, diagnostic pitfall, iatrogenic image].
    Arteaga C; Raillat A; Salamand P; Debonne JM; Bonnet D; Martet G; Veuillet MO; Battini-Nouzille A; Briant JF
    J Radiol; 1998 Feb; 79(2):157-8. PubMed ID: 9757234
    [No Abstract]   [Full Text] [Related]  

  • 16. Detection and segmental location of malignant hepatic tumors: comparison of ferumoxides-enhanced gradient-echo and T2-weighted spin-echo MR imaging.
    Van Beers BE; Lacrosse M; Jamart J; Grandin C; Gigot JF; Horsmans Y; Demeure R; Pringot J
    AJR Am J Roentgenol; 1997 Mar; 168(3):713-7. PubMed ID: 9057521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of liver tumors].
    Rummeny EJ; Reimer P; Daldrup H; Peters PE
    Radiologe; 1995 Nov; 35(11 Suppl 2):S252-8. PubMed ID: 8588031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Superparamagnetic iron oxide particles: what value has the T1 effect in the MR diagnosis of focal liver lesions?].
    Urhahn R; Adam G; Busch N; Chen JH; Euringer W; Günther RW
    Rofo; 1996 Oct; 165(4):364-70. PubMed ID: 8963049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
    Mergo PJ; Helmberger T; Nicolas AI; Ros PR
    AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results with Resovist: a phase 2 clinical trial.
    Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
    Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.